MediWound (MDWD)

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Dagens MediWound Ltd. Ordinary Shares (MDWD) aktiekurs på är , vilket speglar en NaN % rörelse sedan marknaden öppnade. Företagets marknadsvärde är 227,44 mn $, med en daglig handelsvolym på  aktier. Det tidigare stängningspriset var .

Redo att börja? Följ stegen nedan, eller läs vår guide om hur man köper MediWound aktier på Kraken med start från 10 $.